Description
A pan tyrosine kinase inhibitor that primarily targets VEGFR2 (IC50 = 0.035 nM) and c-Met (IC50 = 1.3 nM) but also inhibits RET, c-Kit, AXL, FLT3, and Tie2 (IC50 = 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively); reduces tumor and endothelial cell proliferation, targeting both angiogenesis and metastasis in cancers with dysregulated c-Met and VEGFR signaling
Formal name: N’-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide
Synonyms: BMS-907351|Cabozantinib
Molecular weight: 501.5
CAS: 849217-68-1
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Other Receptor Tyrosine Kinases||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Kinase Inhibitors|VEGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Angiogenesis||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling